PARIS, May 22, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced five-year results from the FAME 2 study, which showed that patients had fewer major adverse cardiac events (MACE) when they received a heart stent guided by Abbott’s fractional flow reserve (FFR) […]